Similarly, the m6A eraser FTO was found to act as an oncogenic agent in acute myeloid leukemia in 2017 (Li et al., 2017[139]), and the small molecule inhibitors FB23 and FB23-2 were found to inhibit the proliferation of acute myeloid leukemia cells in vitro and in vivo in 2019 (Huang et al., 2019[96]). Here, FTO is linked to acute myeloid leukemia.